HC Wainwright Lowers BioLife Solutions (NASDAQ:BLFS) Price Target to $27.00

BioLife Solutions (NASDAQ:BLFS) had its price objective reduced by HC Wainwright from $29.00 to $27.00 in a report issued on Monday morning,Benzinga reports. HC Wainwright currently has a buy rating on the medical equipment provider’s stock. HC Wainwright also issued estimates for BioLife Solutions’ Q1 2025 earnings at ($0.10) EPS, Q2 2025 earnings at ($0.10) EPS, Q3 2025 earnings at ($0.10) EPS, Q4 2025 earnings at ($0.11) EPS and FY2025 earnings at ($0.41) EPS.

BLFS has been the subject of a number of other reports. Craig Hallum lifted their target price on BioLife Solutions from $30.00 to $32.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Northland Securities lifted their target price on BioLife Solutions from $26.00 to $28.00 and gave the company an “outperform” rating in a research note on Friday, August 9th. Finally, TD Cowen lifted their target price on BioLife Solutions from $28.00 to $31.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $27.50.

BioLife Solutions Stock Performance

Shares of BLFS stock opened at $25.39 on Monday. The company has a quick ratio of 1.78, a current ratio of 2.78 and a debt-to-equity ratio of 0.03. The business has a 50 day moving average of $23.96 and a two-hundred day moving average of $22.88. BioLife Solutions has a 52 week low of $11.91 and a 52 week high of $28.88. The company has a market cap of $1.18 billion, a P/E ratio of -23.95 and a beta of 1.88.

Insider Transactions at BioLife Solutions

In related news, CRO Garrie Richardson sold 3,070 shares of the business’s stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $25.12, for a total transaction of $77,118.40. Following the sale, the executive now owns 114,773 shares of the company’s stock, valued at $2,883,097.76. The trade was a 2.61 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Aby J. Mathew sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 15th. The stock was sold at an average price of $23.28, for a total value of $232,800.00. Following the sale, the executive vice president now directly owns 317,716 shares in the company, valued at approximately $7,396,428.48. The trade was a 3.05 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 69,644 shares of company stock worth $1,527,503. Company insiders own 2.20% of the company’s stock.

Institutional Investors Weigh In On BioLife Solutions

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Mark Sheptoff Financial Planning LLC bought a new stake in BioLife Solutions during the third quarter worth approximately $28,000. 1620 Investment Advisors Inc. bought a new position in shares of BioLife Solutions in the second quarter valued at $35,000. Isthmus Partners LLC increased its holdings in shares of BioLife Solutions by 34.4% in the second quarter. Isthmus Partners LLC now owns 165,247 shares of the medical equipment provider’s stock valued at $35,000 after buying an additional 42,265 shares in the last quarter. Quest Partners LLC bought a new position in shares of BioLife Solutions in the third quarter valued at $57,000. Finally, GAMMA Investing LLC increased its holdings in shares of BioLife Solutions by 29.4% in the third quarter. GAMMA Investing LLC now owns 3,295 shares of the medical equipment provider’s stock valued at $83,000 after buying an additional 748 shares in the last quarter. Institutional investors own 93.24% of the company’s stock.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.